AML
News
FDA panel voices concerns over 2 lymphoma accelerated approvals
FDA’s ODAC committee pressed for resolution on whether 2 lymphoma drugs, long on the U.S. market, actually deliver significant benefits to...
News
Study confirms small blood cancer risk from CT scans
New research suggests that radiation exposure from CT scans heightens the risk of blood cancer in people under age 22.
Conference Coverage
FDA’s Project Optimus aims to transform early cancer research
Q & A with an expert on how the FDA’s Project Optimus targets toxicity and how it could spell the end of traditional dose-escalation trials....
News
How targeted drugs can vanquish a virulent leukemia
Targeted therapies have revolutionized the treatment of AML, yet outcomes could be better, and these costly new drugs don’t suit all patients.
News
FDA approves JAK inhibitor momelotinib for myelofibrosis with anemia
Momelotinib is the fourth JAK inhibitor approved by the FDA to treat the anemia that often accompanies myelofibrosis, a rare form of blood cancer...
Conference Coverage
Is additional treatment needed, pretransplant, for r/r AML?
The issue of whether or not patients with r/r AML require additional treatment pretransplant was debated at SOHO 2023.
News
Antibody shows promise in preventing GVHD
In translational research that shows potential for humans, an antibody blockade of the Notch signaling pathway prevents graft-versus-host-disease...
News
FDA approves quizartinib for newly diagnosed AML
Cardiac risks mean the targeted tyrosine kinase inhibitor is available only through a Risk Evaluation and Mitigation Strategies program.
News
ESMO helps hematologists assess new cancer drugs
The group’s new study evaluation tool, the ESMO-MCBS:H, is aimed at helping doctors and others determine the benefit of new blood cancer therapies...
Conference Coverage
Multiprong strategy makes clinical trials less White
Only a small percentage of eligible patients participate in clinical trials in the first place, and very few come from racial and ethnic minority...
